open access

Vol 93, No 7 (2022)
Research paper
Published online: 2021-11-23
Get Citation

Prediction of preterm birth using PAMG-1 test: a single centre experience — preliminary report

Wojciech Cnota1, Agnieszka Jagielska1, Ewa Janowska1, Ewa Banas1, Rafal Kierach1, Malgorzata Nycz-Reska1, Bartosz Czuba1
·
Pubmed: 35072245
·
Ginekol Pol 2022;93(7):574-577.
Affiliations
  1. Clinical Department of Perinatology, Gynaecology and Obstetrics in Ruda Slaska, Medical University of Silesia, Ruda Slaska, Poland, Poland

open access

Vol 93, No 7 (2022)
ORIGINAL PAPERS Obstetrics
Published online: 2021-11-23

Abstract

Objectives: Placental alpha microglobulin-1 (PAMG-1) is a novel biomarker detected in cervicovaginal discharge in patients threatened with preterm birth (PTB). This study aimed to show a single centre experience of assessment of imminent spontaneous PTB risk in patients with symptoms suggesting preterm labour (PTL).

Material and methods: The study group consisted of 46 women with singleton pregnancies between 24 + 0/7 and 33 + 6/7 weeks of gestation who presented with symptoms of threatened PTL, with cervical dilatation of < 3 cm, cervical length (CL) of < 30 mm and clinically intact fetal membranes. CL was measured via transvaginal ultrasound and the PAMG-1 test was performed in all of the objectives.

Results: Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of prediction of PTB within seven days for CL were 100%, 11.11%, 5.88% and 100%, respectively. The PAMG-1 test SN, SP, PPV and NPV of the same endpoint were 50%, 80.56%, 12.5% and 96.67%, respectively.

Conclusions: PAMG-1 is a more accurate predictor of PTB when compared to CL. Routine use of both mentioned tests could allow identification of low-risk patients and reduction of rate of unnecessary hospitalizations and treatments.

Abstract

Objectives: Placental alpha microglobulin-1 (PAMG-1) is a novel biomarker detected in cervicovaginal discharge in patients threatened with preterm birth (PTB). This study aimed to show a single centre experience of assessment of imminent spontaneous PTB risk in patients with symptoms suggesting preterm labour (PTL).

Material and methods: The study group consisted of 46 women with singleton pregnancies between 24 + 0/7 and 33 + 6/7 weeks of gestation who presented with symptoms of threatened PTL, with cervical dilatation of < 3 cm, cervical length (CL) of < 30 mm and clinically intact fetal membranes. CL was measured via transvaginal ultrasound and the PAMG-1 test was performed in all of the objectives.

Results: Sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) of prediction of PTB within seven days for CL were 100%, 11.11%, 5.88% and 100%, respectively. The PAMG-1 test SN, SP, PPV and NPV of the same endpoint were 50%, 80.56%, 12.5% and 96.67%, respectively.

Conclusions: PAMG-1 is a more accurate predictor of PTB when compared to CL. Routine use of both mentioned tests could allow identification of low-risk patients and reduction of rate of unnecessary hospitalizations and treatments.

Get Citation

Keywords

preterm birth, preterm labou; placental alpha microglobulin-1 (PAMG-1); PartoSure; cervical length (CL)

About this article
Title

Prediction of preterm birth using PAMG-1 test: a single centre experience — preliminary report

Journal

Ginekologia Polska

Issue

Vol 93, No 7 (2022)

Article type

Research paper

Pages

574-577

Published online

2021-11-23

Page views

4669

Article views/downloads

709

DOI

10.5603/GP.a2021.0171

Pubmed

35072245

Bibliographic record

Ginekol Pol 2022;93(7):574-577.

Keywords

preterm birth
preterm labou
placental alpha microglobulin-1 (PAMG-1)
PartoSure
cervical length (CL)

Authors

Wojciech Cnota
Agnieszka Jagielska
Ewa Janowska
Ewa Banas
Rafal Kierach
Malgorzata Nycz-Reska
Bartosz Czuba

References (17)
  1. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012; 379(9832): 2162–2172.
  2. Althabe F, Howson CP, Kinney M. World Health Organization Born too soon: the global action report on preterm birth. 2012.
  3. WARD R. Neonatal complications following preterm birth. BJOG: An International Journal of Obstetrics and Gynaecology. 2003; 110: 8–16.
  4. Koullali B, Oudijk MA, Nijman TAJ, et al. Risk assessment and management to prevent preterm birth. Semin Fetal Neonatal Med. 2016; 21(2): 80–88.
  5. Sanchez-Ramos L, Delke I, Zamora J, et al. Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients. Obstetric Anesthesia Digest. 2010; 30(4): 214–215.
  6. Sotiriadis A, Papatheodorou S, Kavvadias A, et al. Transvaginal cervical length measurement for prediction of preterm birth in women with threatened preterm labor: a meta-analysis. Ultrasound Obstet Gynecol. 2010; 35(1): 54–64.
  7. Empana JP, Anceschi MM, Szabo I, et al. EURAIL Study Group. Antenatal corticosteroids policies in 14 European countries: factors associated with multiple courses. The EURAIL survey. Acta Paediatr. 2004; 93(10): 1318–1322.
  8. Peltoniemi OM, Kari MA, Tammela O, et al. Repeat Antenatal Betamethasone Study Group. Randomized trial of a single repeat dose of prenatal betamethasone treatment in imminent preterm birth. Pediatrics. 2007; 119(2): 290–298.
  9. Dunlop S, Archer M, Quinlivan J, et al. Repeated prenatal corticosteroids delay myelination in the ovine central nervous system. Journal of Maternal-Fetal and Neonatal Medicine. 1997; 6(6): 309–313.
  10. Nikolova T, Bayev O, Nikolova N, et al. Evaluation of a novel placental alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery. J Perinat Med. 2014; 42(4): 473–477.
  11. Nikolova T, Bayev O, Nikolova N, et al. Comparison of a novel test for placental alpha microglobulin-1 with fetal fibronectin and cervical length measurement for the prediction of imminent spontaneous preterm delivery in patients with threatened preterm labor. J Perinat Med. 2015; 43(4): 395–402.
  12. Lee SMi, Romero R, Park JW, et al. The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes. J Matern Fetal Neonatal Med. 2012; 25(9): 1690–1698.
  13. Tripathi R, Tyagi S, Mala YM, et al. Comparison of rapid bedside tests for phosphorylated insulin-like growth factor-binding protein 1 and fetal fibronectin to predict preterm birth. Int J Gynaecol Obstet. 2016; 135(1): 47–50.
  14. Cooper S, Lange I, Wood S, et al. Diagnostic accuracy of rapid phIGFBP-I assay for predicting preterm labor in symptomatic patients. J Perinatol. 2012; 32(6): 460–465.
  15. Bolotskikh V, Borisova V. Combined value of placental alpha microglobulin-1 detection and cervical length via transvaginal ultrasound in the diagnosis of preterm labor in symptomatic patients. J Obstet Gynaecol Res. 2017; 43(8): 1263–1269.
  16. Lucovnik M, Chambliss LR, Garfield RE. Costs of unnecessary admissions and treatments for "threatened preterm labor". Am J Obstet Gynecol. 2013; 209(3): 217.e1–217.e3.
  17. Melchor JC, Khalil A, Wing D, et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 52(4): 442–451.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl